Cancer metabolism: a therapeutic perspective (Q38824435)

6 September 2017

1 reference

title

Cancer metabolism: a therapeutic perspective. (English)

1 reference

Ubaldo E Martinez-Outschoorn

6 September 2017

series ordinal

1

1 reference

6 September 2017

5

Michael P Lisanti

1 reference

6 September 2017

4

Federica Sotgia

1 reference

6 September 2017

3

Richard G Pestell

1 reference

6 September 2017

Maria Peiris-Pagés

2

1 reference

PubMed ID

27141887

6 September 2017

language of work or name

English

0 references

publication date

4 May 2016

1 reference

Nature Reviews Clinical Oncology

6 September 2017

1 reference

6 September 2017

14

1 reference

6 September 2017

1

1 reference

6 September 2017

11-31

1 reference

https://scigraph.springernature.com/pub.10.1038/nrclinonc.2016.60

6 September 2017

0 references

cites work

Mitochondria as biosynthetic factories for cancer proliferation.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Understanding the Warburg effect: the metabolic requirements of cell proliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Cooperation and competition in the evolution of ATP-producing pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Ecology. The advantages of togetherness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Cancer metabolism: facts, fantasy, and fiction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Modeling Alveolar Soft Part Sarcomagenesis in the Mouse: A Role for Lactate in the Tumor Microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Targeting lactate metabolism for cancer therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Acetyl coenzyme A: a central metabolite and second messenger

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Hallmarks of Cancer: The Next Generation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

31 March 2020

Mitochondria and cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Metabolic pathways promoting cancer cell survival and growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Metabolic targets for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H(+) symporters

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Targeting tumor microenvironment with silibinin: promise and potential for a translational cancer chemopreventive strategy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Molecular Pathways: Targeting Cellular Energy Metabolism in Cancer via Inhibition of SLC2A1 and LDHA

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Identification of small molecule inhibitors of pyruvate kinase M2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Methyl jasmonate binds to and detaches mitochondria-bound hexokinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Plasma free amino acid profile in cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Glutamine and cancer: cell biology, physiology, and clinical opportunities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Reductive carboxylation supports growth in tumour cells with defective mitochondria.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Association of reactive oxygen species levels and radioresistance in cancer stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Glutamine-fueled mitochondrial metabolism is decoupled from glycolysis in melanoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Glucose and glutamine metabolism in oral squamous cell carcinoma: insight from a quantitative metabolomic approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Lactate: a metabolic key player in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Catabolism of exogenous lactate reveals it as a legitimate metabolic substrate in breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Lactate in solid malignant tumors: potential basis of a metabolic classification in clinical oncology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

T cell exclusion, immune privilege, and the tumor microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Functional polarization of tumour-associated macrophages by tumour-derived lactic acid.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Power surge: supporting cells "fuel" cancer cell mitochondria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Metabolic reprogramming of cancer-associated fibroblasts by IDH3α downregulation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Monocarboxylic acid transport

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

31 March 2020

Sweet sixteen for ANLS.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Neuroscience. Metabolic control of epilepsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Epilepsy treatment. Targeting LDH enzymes with a stiripentol analog to treat epilepsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Targeting the metabolic microenvironment of tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Recent Update on Human Lactate Dehydrogenase Enzyme 5 (hLDH5) Inhibitors: A Promising Approach for Cancer Chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Lactate dehydrogenase M-subunit deficiency: a new type of hereditary exertional myopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Pyruvate fuels mitochondrial respiration and proliferation of breast cancer cells: effect of monocarboxylate transporter inhibition.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

ATP citrate lyase inhibition can suppress tumor cell growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Activation of a metabolic gene regulatory network downstream of mTOR complex 1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Erk regulation of pyruvate dehydrogenase flux through PDK4 modulates cell proliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

31 March 2020

Autophagy and metabolism

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Microbial ecology: human gut microbes associated with obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

The impact of the gut microbiota on human health: an integrative view

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Gastrointestinal malignancy and the microbiome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Ketosis, ketogenic diet and food intake control: a complex relationship

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

p53 in survival, death and metabolic health: a lifeguard with a licence to kill

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Hypoxia promotes tumor cell survival in acidic conditions by preserving ATP levels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Hypoxia induces triglycerides accumulation in prostate cancer cells and extracellular vesicles supporting growth and invasiveness following reoxygenation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Drug repurposing in oncology--patient and health systems opportunities.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Targeting glucose metabolism for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Standing the test of time: targeting thymidylate biosynthesis in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Functional genomics reveal that the serine synthesis pathway is essential in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

NRF2 regulates serine biosynthesis in non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Molecular Pathways: Targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

MYC, Metabolism, and Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Human phosphoglycerate dehydrogenase produces the oncometabolite D-2-hydroxyglutarate.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Cloning, expression, activity and folding studies of serine hydroxymethyltransferase: a target enzyme for cancer chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Quantitative flux analysis reveals folate-dependent NADPH production.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

ATP citrate lyase is an important component of cell growth and transformation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

A novel small molecule antagonist of choline kinase-α that simultaneously suppresses MAPK and PI3K/AKT signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Fatty acid synthase as a potential therapeutic target in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Therapeutic potential of monoacylglycerol lipase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Involvement of human choline kinase alpha and beta in carcinogenesis: a different role in lipid metabolism and biological functions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Choline metabolism in malignant transformation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Statins in oncological research: from experimental studies to clinical practice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Statin use and reduced cancer-related mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Mitochondrial p32 protein is a critical regulator of tumor metabolism via maintenance of oxidative phosphorylation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Nanoscale distribution of mitochondrial import receptor Tom20 is adjusted to cellular conditions and exhibits an inner-cellular gradient

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

PINK1 and Parkin control localized translation of respiratory chain component mRNAs on mitochondria outer membrane.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Stem cells. Asymmetric apportioning of aged mitochondria between daughter cells is required for stemness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Retinoic acid and arsenic trioxide for acute promyelocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Overcoming Drug Development Bottlenecks With Repurposing: Repurposing biguanides to target energy metabolism for cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Metformin is synthetically lethal with glucose withdrawal in cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Metformin: from mechanisms of action to therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Metformin, cancer and glucose metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Phase I trial of the selective mitochondrial toxin MKT 077 in chemo-resistant solid tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Mutant metabolic enzymes are at the origin of gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

On the origin of mitosing cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Structural biology. Mitoribosome oddities.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Ribosome. The complete structure of the 55S mammalian mitochondrial ribosome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Ribosome. The structure of the human mitochondrial ribosome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Structure of the Yeast Mitochondrial Large Ribosomal Subunit

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Structure of the large ribosomal subunit from human mitochondria.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Ribosome-targeting antibiotics and mechanisms of bacterial resistance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Interaction of antibiotics with functional sites in 16S ribosomal RNA

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Prevalence of Mitochondrial 1555A→G Mutation in European Children

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Mitochondrial toxicity associated with linezolid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Tetracyclines: drugs with huge therapeutic potential

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Oncometabolites: linking altered metabolism with cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Catabolic efficiency of aerobic glycolysis: the Warburg effect revisited

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Genome-scale metabolic modeling elucidates the role of proliferative adaptation in causing the Warburg effect

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Physiological roles of mitochondrial reactive oxygen species

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Altered mitochondrial function and metabolic inflexibility associated with loss of caveolin-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

The genomic analysis of lactic acidosis and acidosis response in human cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Beyond Warburg effect--dual metabolic nature of cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Modulation of oxidative stress as an anticancer strategy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

NAMPT in regulated NAD biosynthesis and its pivotal role in human metabolism.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

A mitochondrial switch promotes tumor metastasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Peptide and small molecule inhibitors of the Keap1-Nrf2 protein-protein interaction.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

HIF-1α can act as a tumor suppressor gene in murine acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Targeting hypoxia in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Tumor aerobic glycolysis: new insights into therapeutic strategies with targeted delivery.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Ecology meets cancer biology: the cancer swamp promotes the lethal cancer phenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Deconvoluting the context-dependent role for autophagy in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Current treatment strategies for inhibiting mTOR in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Chloroquine in cancer therapy: a double-edged sword of autophagy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Influence of metabolism on epigenetics and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Reductive carboxylation and 2-hydroxyglutarate formation by wild-type IDH2 in breast carcinoma cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Hypoxia Induces Production of L-2-Hydroxyglutarate.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Metabolism and epigenetics: a link cancer cells exploit.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Metastasis and Oxidative Stress: Are Antioxidants a Metabolic Driver of Progression?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Targeting lactate transport suppresses in vivo breast tumour growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

PDK1 inhibition is a novel therapeutic target in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Metformin and cancer: Between the bioenergetic disturbances and the antifolate activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Phosphoglycerate Mutase 1 Coordinates Glycolysis and Biosynthesis to Promote Tumor Growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Arginine deprivation in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Autophagy in malignant transformation and cancer progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Dissecting the Dual Role of AMPK in Cancer: From Experimental to Human Studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Antioxidants accelerate lung cancer progression in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Warburg meets autophagy: cancer-associated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy, and aerobic glycolysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.60

Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain

31 March 2020

1 reference

12 December 2020

Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy

1 reference

12 December 2020

Structure and Function of the Mitochondrial Ribosome

1 reference

12 December 2020

Dissecting tumor metabolic heterogeneity: Telomerase and large cell size metabolically define a sub-population of stem-like, mitochondrial-rich, cancer cells

1 reference

12 December 2020

FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis

1 reference

12 December 2020

Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells

1 reference

12 December 2020

Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice

1 reference

12 December 2020

Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease

1 reference

12 December 2020

A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077

1 reference

12 December 2020

10.1038/NRCLINONC.2016.60

Identifiers

DOI

1 reference

PubMed ID

27141887

Dimensions Publication ID

6 September 2017

0 references

1 reference

PubMed ID

27141887